nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—urinary bladder cancer—prostate cancer	0.123	0.363	CtDrD
Methotrexate—bone cancer—prostate cancer	0.118	0.348	CtDrD
Methotrexate—AOX1—prostate cancer	0.113	0.571	CbGaD
Methotrexate—testicular cancer—prostate cancer	0.0977	0.289	CtDrD
Methotrexate—TYMS—prostate cancer	0.0472	0.239	CbGaD
Methotrexate—MTHFR—prostate cancer	0.0376	0.19	CbGaD
Methotrexate—ABCC11—Conjugated Estrogens—prostate cancer	0.0239	0.0812	CbGbCtD
Methotrexate—SLCO3A1—Conjugated Estrogens—prostate cancer	0.0164	0.0558	CbGbCtD
Methotrexate—TYMS—Capecitabine—prostate cancer	0.0148	0.0501	CbGbCtD
Methotrexate—AOX1—Ethinyl Estradiol—prostate cancer	0.0135	0.0459	CbGbCtD
Methotrexate—SLCO1C1—Conjugated Estrogens—prostate cancer	0.0105	0.0356	CbGbCtD
Methotrexate—SLCO1C1—Estradiol—prostate cancer	0.00922	0.0313	CbGbCtD
Methotrexate—ABCC10—Estradiol—prostate cancer	0.00922	0.0313	CbGbCtD
Methotrexate—SLCO1B3—Cabazitaxel—prostate cancer	0.00918	0.0311	CbGbCtD
Methotrexate—AOX1—Estradiol—prostate cancer	0.00873	0.0296	CbGbCtD
Methotrexate—ABCC1—Abiraterone—prostate cancer	0.00858	0.0291	CbGbCtD
Methotrexate—ABCC3—Conjugated Estrogens—prostate cancer	0.00661	0.0224	CbGbCtD
Methotrexate—ABCC10—Etoposide—prostate cancer	0.00602	0.0204	CbGbCtD
Methotrexate—SLCO1B3—Conjugated Estrogens—prostate cancer	0.00587	0.0199	CbGbCtD
Methotrexate—SLCO1A2—Estrone—prostate cancer	0.00554	0.0188	CbGbCtD
Methotrexate—ABCC10—Docetaxel—prostate cancer	0.00551	0.0187	CbGbCtD
Methotrexate—SLC22A11—Conjugated Estrogens—prostate cancer	0.00542	0.0184	CbGbCtD
Methotrexate—SLCO1B1—Cabazitaxel—prostate cancer	0.00534	0.0181	CbGbCtD
Methotrexate—SLCO1B1—Estrone—prostate cancer	0.00522	0.0177	CbGbCtD
Methotrexate—SLCO1B3—Estradiol—prostate cancer	0.00515	0.0175	CbGbCtD
Methotrexate—ABCC4—Conjugated Estrogens—prostate cancer	0.00505	0.0171	CbGbCtD
Methotrexate—SLC22A11—Estradiol—prostate cancer	0.00476	0.0162	CbGbCtD
Methotrexate—ABCG2—Cabazitaxel—prostate cancer	0.00425	0.0144	CbGbCtD
Methotrexate—ABCG2—Estrone—prostate cancer	0.00415	0.0141	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—prostate cancer	0.00411	0.0139	CbGbCtD
Methotrexate—ABCC2—Ethinyl Estradiol—prostate cancer	0.00409	0.0139	CbGbCtD
Methotrexate—ABCC1—Conjugated Estrogens—prostate cancer	0.00406	0.0138	CbGbCtD
Methotrexate—ALB—Abiraterone—prostate cancer	0.00396	0.0134	CbGbCtD
Methotrexate—ABCC3—Etoposide—prostate cancer	0.00379	0.0128	CbGbCtD
Methotrexate—ABCC1—Mitoxantrone—prostate cancer	0.00369	0.0125	CbGbCtD
Methotrexate—SLCO1A2—Conjugated Estrogens—prostate cancer	0.00362	0.0123	CbGbCtD
Methotrexate—SLCO1B1—Conjugated Estrogens—prostate cancer	0.00342	0.0116	CbGbCtD
Methotrexate—SLCO1A2—Estradiol—prostate cancer	0.00318	0.0108	CbGbCtD
Methotrexate—SLC22A8—Conjugated Estrogens—prostate cancer	0.00315	0.0107	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—prostate cancer	0.00308	0.0104	CbGbCtD
Methotrexate—ABCC2—Conjugated Estrogens—prostate cancer	0.003	0.0102	CbGbCtD
Methotrexate—SLCO1B1—Estradiol—prostate cancer	0.003	0.0102	CbGbCtD
Methotrexate—ABCC1—Epirubicin—prostate cancer	0.00298	0.0101	CbGbCtD
Methotrexate—ALB—Estrone—prostate cancer	0.00286	0.0097	CbGbCtD
Methotrexate—SLC22A8—Estradiol—prostate cancer	0.00277	0.00939	CbGbCtD
Methotrexate—SLCO1A2—Prednisone—prostate cancer	0.00273	0.00928	CbGbCtD
Methotrexate—ABCG2—Conjugated Estrogens—prostate cancer	0.00271	0.00921	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—prostate cancer	0.00271	0.00919	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—prostate cancer	0.00258	0.00876	CbGbCtD
Methotrexate—ABCG2—Mitoxantrone—prostate cancer	0.00247	0.00837	CbGbCtD
Methotrexate—ABCG2—Estradiol—prostate cancer	0.00238	0.00808	CbGbCtD
Methotrexate—ABCC1—Etoposide—prostate cancer	0.00233	0.00789	CbGbCtD
Methotrexate—ABCB1—Estramustine—prostate cancer	0.00232	0.00788	CbGbCtD
Methotrexate—SLC22A6—Conjugated Estrogens—prostate cancer	0.0022	0.00745	CbGbCtD
Methotrexate—ABCC1—Docetaxel—prostate cancer	0.00213	0.00722	CbGbCtD
Methotrexate—ABCC2—Etoposide—prostate cancer	0.00172	0.00584	CbGbCtD
Methotrexate—ALB—Estradiol—prostate cancer	0.00164	0.00557	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—prostate cancer	0.00159	0.00538	CbGbCtD
Methotrexate—ABCC2—Docetaxel—prostate cancer	0.00157	0.00534	CbGbCtD
Methotrexate—ABCG2—Etoposide—prostate cancer	0.00156	0.00528	CbGbCtD
Methotrexate—ABCB1—Cabazitaxel—prostate cancer	0.00153	0.00519	CbGbCtD
Methotrexate—ABCB1—Estrone—prostate cancer	0.0015	0.00508	CbGbCtD
Methotrexate—ABCG2—Docetaxel—prostate cancer	0.00142	0.00483	CbGbCtD
Methotrexate—ALB—Prednisone—prostate cancer	0.00141	0.00479	CbGbCtD
Methotrexate—ABCB1—Ethinyl Estradiol—prostate cancer	0.00133	0.00452	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—prostate cancer	0.00117	0.00398	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—prostate cancer	0.00106	0.0036	CbGbCtD
Methotrexate—ABCB1—Conjugated Estrogens—prostate cancer	0.000979	0.00332	CbGbCtD
Methotrexate—FOLR1—prostate gland—prostate cancer	0.000961	0.0307	CbGeAlD
Methotrexate—ABCB1—Mitoxantrone—prostate cancer	0.00089	0.00302	CbGbCtD
Methotrexate—ABCB1—Estradiol—prostate cancer	0.000859	0.00292	CbGbCtD
Methotrexate—SLC19A1—prostate gland—prostate cancer	0.000842	0.0269	CbGeAlD
Methotrexate—FOLR1—seminal vesicle—prostate cancer	0.000812	0.0259	CbGeAlD
Methotrexate—ABCB1—Prednisone—prostate cancer	0.000739	0.00251	CbGbCtD
Methotrexate—FOLR1—epithelium—prostate cancer	0.000706	0.0225	CbGeAlD
Methotrexate—SLC22A8—urine—prostate cancer	0.000689	0.022	CbGeAlD
Methotrexate—FOLR1—renal system—prostate cancer	0.000655	0.0209	CbGeAlD
Methotrexate—SLC46A1—prostate gland—prostate cancer	0.000649	0.0207	CbGeAlD
Methotrexate—GGH—prostate gland—prostate cancer	0.000638	0.0204	CbGeAlD
Methotrexate—FPGS—prostate gland—prostate cancer	0.000561	0.0179	CbGeAlD
Methotrexate—ABCB1—Etoposide—prostate cancer	0.000561	0.0019	CbGbCtD
Methotrexate—SLC46A1—seminal vesicle—prostate cancer	0.000549	0.0175	CbGeAlD
Methotrexate—ATIC—prostate gland—prostate cancer	0.000543	0.0173	CbGeAlD
Methotrexate—GGH—seminal vesicle—prostate cancer	0.00054	0.0172	CbGeAlD
Methotrexate—ABCB1—Docetaxel—prostate cancer	0.000513	0.00174	CbGbCtD
Methotrexate—SLCO4C1—seminal vesicle—prostate cancer	0.000479	0.0153	CbGeAlD
Methotrexate—FPGS—seminal vesicle—prostate cancer	0.000475	0.0151	CbGeAlD
Methotrexate—GGH—renal system—prostate cancer	0.000435	0.0139	CbGeAlD
Methotrexate—GGH—urethra—prostate cancer	0.000427	0.0136	CbGeAlD
Methotrexate—ABCC11—testis—prostate cancer	0.000406	0.0129	CbGeAlD
Methotrexate—MTHFR—prostate gland—prostate cancer	0.000403	0.0129	CbGeAlD
Methotrexate—ATIC—epithelium—prostate cancer	0.000399	0.0127	CbGeAlD
Methotrexate—SLCO3A1—prostate gland—prostate cancer	0.000397	0.0127	CbGeAlD
Methotrexate—SLCO4C1—renal system—prostate cancer	0.000386	0.0123	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—prostate cancer	0.000383	0.0013	CbGbCtD
Methotrexate—FPGS—urethra—prostate cancer	0.000376	0.012	CbGeAlD
Methotrexate—SLC19A1—testis—prostate cancer	0.000371	0.0118	CbGeAlD
Methotrexate—ATIC—renal system—prostate cancer	0.00037	0.0118	CbGeAlD
Methotrexate—TYMS—prostate gland—prostate cancer	0.000368	0.0117	CbGeAlD
Methotrexate—TYMS—Docetaxel—Cabazitaxel—prostate cancer	0.000365	0.313	CbGdCrCtD
Methotrexate—DHFR—prostate gland—prostate cancer	0.000364	0.0116	CbGeAlD
Methotrexate—Raltitrexed—TYMS—prostate cancer	0.000364	0.242	CrCbGaD
Methotrexate—PGD—prostate gland—prostate cancer	0.00035	0.0112	CbGeAlD
Methotrexate—SLCO3A1—seminal vesicle—prostate cancer	0.000336	0.0107	CbGeAlD
Methotrexate—GGH—bone marrow—prostate cancer	0.000329	0.0105	CbGeAlD
Methotrexate—SLC16A1—prostate gland—prostate cancer	0.000327	0.0104	CbGeAlD
Methotrexate—AOX1—prostate gland—prostate cancer	0.000309	0.00985	CbGeAlD
Methotrexate—DHFR—seminal vesicle—prostate cancer	0.000308	0.00984	CbGeAlD
Methotrexate—SLCO1C1—renal system—prostate cancer	0.000308	0.00982	CbGeAlD
Methotrexate—ABCC3—prostate gland—prostate cancer	0.000302	0.00964	CbGeAlD
Methotrexate—ABCC10—prostate gland—prostate cancer	0.0003	0.00959	CbGeAlD
Methotrexate—SLC22A11—renal system—prostate cancer	0.000299	0.00953	CbGeAlD
Methotrexate—PGD—seminal vesicle—prostate cancer	0.000296	0.00946	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—prostate cancer	0.000292	0.00931	CbGeAlD
Methotrexate—SLC22A7—renal system—prostate cancer	0.000292	0.00931	CbGeAlD
Methotrexate—SLC46A1—testis—prostate cancer	0.000286	0.00912	CbGeAlD
Methotrexate—GGH—testis—prostate cancer	0.000281	0.00898	CbGeAlD
Methotrexate—Leucovorin—TYMS—prostate cancer	0.000276	0.183	CrCbGaD
Methotrexate—Pralatrexate—TYMS—prostate cancer	0.000276	0.183	CrCbGaD
Methotrexate—SLCO3A1—renal system—prostate cancer	0.000271	0.00863	CbGeAlD
Methotrexate—SLC19A1—lymph node—prostate cancer	0.000269	0.00858	CbGeAlD
Methotrexate—SLCO3A1—urethra—prostate cancer	0.000266	0.00848	CbGeAlD
Methotrexate—AOX1—seminal vesicle—prostate cancer	0.000261	0.00833	CbGeAlD
Methotrexate—ABCC10—seminal vesicle—prostate cancer	0.000254	0.00811	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Cabazitaxel—prostate cancer	0.000252	0.216	CbGdCrCtD
Methotrexate—ABCC4—prostate gland—prostate cancer	0.000249	0.00795	CbGeAlD
Methotrexate—DHFR—renal system—prostate cancer	0.000248	0.00793	CbGeAlD
Methotrexate—SLC22A8—prostate gland—prostate cancer	0.000247	0.00789	CbGeAlD
Methotrexate—FPGS—testis—prostate cancer	0.000247	0.00789	CbGeAlD
Methotrexate—DHFR—urethra—prostate cancer	0.000244	0.00779	CbGeAlD
Methotrexate—ABCC2—prostate gland—prostate cancer	0.000241	0.0077	CbGeAlD
Methotrexate—SLC16A1—epithelium—prostate cancer	0.00024	0.00767	CbGeAlD
Methotrexate—ATIC—testis—prostate cancer	0.000239	0.00763	CbGeAlD
Methotrexate—PGD—renal system—prostate cancer	0.000239	0.00762	CbGeAlD
Methotrexate—PGD—urethra—prostate cancer	0.000235	0.00749	CbGeAlD
Methotrexate—SLC16A1—renal system—prostate cancer	0.000223	0.00712	CbGeAlD
Methotrexate—Pemetrexed—TYMS—prostate cancer	0.00022	0.147	CrCbGaD
Methotrexate—SLCO1B1—renal system—prostate cancer	0.000217	0.00692	CbGeAlD
Methotrexate—ABCC1—prostate gland—prostate cancer	0.000212	0.00678	CbGeAlD
Methotrexate—AOX1—renal system—prostate cancer	0.00021	0.00672	CbGeAlD
Methotrexate—SLC46A1—lymph node—prostate cancer	0.000207	0.00661	CbGeAlD
Methotrexate—AOX1—urethra—prostate cancer	0.000207	0.0066	CbGeAlD
Methotrexate—ABCC3—renal system—prostate cancer	0.000206	0.00657	CbGeAlD
Methotrexate—ABCC10—renal system—prostate cancer	0.000205	0.00654	CbGeAlD
Methotrexate—GGH—lymph node—prostate cancer	0.000204	0.00651	CbGeAlD
Methotrexate—ABCC10—urethra—prostate cancer	0.000201	0.00642	CbGeAlD
Methotrexate—SLCO1C1—testis—prostate cancer	0.000199	0.00634	CbGeAlD
Methotrexate—TYMS—bone marrow—prostate cancer	0.00019	0.00605	CbGeAlD
Methotrexate—SLC22A7—testis—prostate cancer	0.000188	0.00601	CbGeAlD
Methotrexate—DHFR—bone marrow—prostate cancer	0.000188	0.00599	CbGeAlD
Methotrexate—PGD—bone marrow—prostate cancer	0.000181	0.00576	CbGeAlD
Methotrexate—ABCC1—seminal vesicle—prostate cancer	0.00018	0.00574	CbGeAlD
Methotrexate—FPGS—lymph node—prostate cancer	0.000179	0.00572	CbGeAlD
Methotrexate—MTHFR—testis—prostate cancer	0.000178	0.00567	CbGeAlD
Methotrexate—SLCO1A2—renal system—prostate cancer	0.000176	0.00563	CbGeAlD
Methotrexate—ABCG2—prostate gland—prostate cancer	0.000176	0.00561	CbGeAlD
Methotrexate—SLCO3A1—testis—prostate cancer	0.000175	0.00558	CbGeAlD
Methotrexate—ATIC—lymph node—prostate cancer	0.000173	0.00553	CbGeAlD
Methotrexate—ABCC4—renal system—prostate cancer	0.00017	0.00542	CbGeAlD
Methotrexate—SLC22A8—renal system—prostate cancer	0.000169	0.00538	CbGeAlD
Methotrexate—ABCC2—renal system—prostate cancer	0.000164	0.00525	CbGeAlD
Methotrexate—TYMS—testis—prostate cancer	0.000162	0.00518	CbGeAlD
Methotrexate—DHFR—testis—prostate cancer	0.000161	0.00512	CbGeAlD
Methotrexate—ABCC10—bone marrow—prostate cancer	0.000155	0.00494	CbGeAlD
Methotrexate—PGD—testis—prostate cancer	0.000154	0.00493	CbGeAlD
Methotrexate—ABCG2—seminal vesicle—prostate cancer	0.000149	0.00475	CbGeAlD
Methotrexate—SLC16A1—testis—prostate cancer	0.000144	0.0046	CbGeAlD
Methotrexate—SLCO1C1—lymph node—prostate cancer	0.000144	0.0046	CbGeAlD
Methotrexate—ABCC1—urethra—prostate cancer	0.000142	0.00454	CbGeAlD
Methotrexate—Folic Acid—MTHFR—prostate cancer	0.000141	0.0939	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—prostate cancer	0.000141	0.0939	CrCbGaD
Methotrexate—AOX1—testis—prostate cancer	0.000136	0.00434	CbGeAlD
Methotrexate—ABCC3—testis—prostate cancer	0.000133	0.00425	CbGeAlD
Methotrexate—ABCC10—testis—prostate cancer	0.000132	0.00422	CbGeAlD
Methotrexate—MTHFR—lymph node—prostate cancer	0.000129	0.00411	CbGeAlD
Methotrexate—ABCC4—bone marrow—prostate cancer	0.000128	0.0041	CbGeAlD
Methotrexate—SLCO3A1—lymph node—prostate cancer	0.000127	0.00405	CbGeAlD
Methotrexate—ATIC—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.000119	0.102	CbGdCrCtD
Methotrexate—ABCG2—urethra—prostate cancer	0.000118	0.00376	CbGeAlD
Methotrexate—TYMS—lymph node—prostate cancer	0.000118	0.00375	CbGeAlD
Methotrexate—DHFR—lymph node—prostate cancer	0.000116	0.00371	CbGeAlD
Methotrexate—SLCO1A2—testis—prostate cancer	0.000114	0.00364	CbGeAlD
Methotrexate—ALB—testis—prostate cancer	0.000113	0.00362	CbGeAlD
Methotrexate—PGD—lymph node—prostate cancer	0.000112	0.00357	CbGeAlD
Methotrexate—ABCC4—testis—prostate cancer	0.00011	0.0035	CbGeAlD
Methotrexate—ABCC2—testis—prostate cancer	0.000106	0.00339	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Docetaxel—prostate cancer	0.000105	0.0897	CbGdCrCtD
Methotrexate—SLC16A1—lymph node—prostate cancer	0.000104	0.00333	CbGeAlD
Methotrexate—AOX1—lymph node—prostate cancer	9.86e-05	0.00315	CbGeAlD
Methotrexate—ABCC3—lymph node—prostate cancer	9.64e-05	0.00308	CbGeAlD
Methotrexate—ABCC10—lymph node—prostate cancer	9.59e-05	0.00306	CbGeAlD
Methotrexate—ABCC1—testis—prostate cancer	9.36e-05	0.00299	CbGeAlD
Methotrexate—ABCG2—bone marrow—prostate cancer	9.07e-05	0.00289	CbGeAlD
Methotrexate—ABCB1—prostate gland—prostate cancer	8.67e-05	0.00277	CbGeAlD
Methotrexate—Folic Acid—CYP2E1—prostate cancer	8.59e-05	0.0571	CrCbGaD
Methotrexate—ALB—lymph node—prostate cancer	8.22e-05	0.00262	CbGeAlD
Methotrexate—ABCC4—lymph node—prostate cancer	7.96e-05	0.00254	CbGeAlD
Methotrexate—ABCG2—testis—prostate cancer	7.75e-05	0.00247	CbGeAlD
Methotrexate—ABCC2—lymph node—prostate cancer	7.7e-05	0.00246	CbGeAlD
Methotrexate—ABCB1—seminal vesicle—prostate cancer	7.34e-05	0.00234	CbGeAlD
Methotrexate—ABCC1—lymph node—prostate cancer	6.79e-05	0.00217	CbGeAlD
Methotrexate—TYMS—Podofilox—Etoposide—prostate cancer	6.71e-05	0.0576	CbGdCrCtD
Methotrexate—TYMS—Levorphanol—Estrone—prostate cancer	6.65e-05	0.0571	CbGdCrCtD
Methotrexate—ABCB1—epithelium—prostate cancer	6.37e-05	0.00203	CbGeAlD
Methotrexate—ABCB1—renal system—prostate cancer	5.91e-05	0.00189	CbGeAlD
Methotrexate—ABCB1—urethra—prostate cancer	5.81e-05	0.00185	CbGeAlD
Methotrexate—ABCG2—lymph node—prostate cancer	5.62e-05	0.00179	CbGeAlD
Methotrexate—TYMS—Levorphanol—Estradiol—prostate cancer	5.04e-05	0.0433	CbGdCrCtD
Methotrexate—ABCB1—bone marrow—prostate cancer	4.47e-05	0.00143	CbGeAlD
Methotrexate—ABCB1—testis—prostate cancer	3.82e-05	0.00122	CbGeAlD
Methotrexate—TYMS—Danazol—Ethinyl Estradiol—prostate cancer	3.33e-05	0.0286	CbGdCrCtD
Methotrexate—ABCB1—lymph node—prostate cancer	2.77e-05	0.000884	CbGeAlD
Methotrexate—TYMS—Levonorgestrel—Ethinyl Estradiol—prostate cancer	2.39e-05	0.0205	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Prednisone—prostate cancer	1.55e-05	0.0133	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Prednisone—prostate cancer	1.53e-05	0.0131	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Prednisone—prostate cancer	1.51e-05	0.013	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Prednisone—prostate cancer	1.39e-05	0.0119	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Prednisone—prostate cancer	1.22e-05	0.0105	CbGdCrCtD
Methotrexate—Stomatitis—Doxorubicin—prostate cancer	1.17e-05	0.000148	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—prostate cancer	1.17e-05	0.000148	CcSEcCtD
Methotrexate—Malaise—Prednisone—prostate cancer	1.17e-05	0.000148	CcSEcCtD
Methotrexate—TYMS—Danazol—Prednisone—prostate cancer	1.17e-05	0.01	CbGdCrCtD
Methotrexate—Abdominal pain—Etoposide—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Nervous system disorder—Capecitabine—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Vertigo—Prednisone—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—prostate cancer	1.17e-05	0.000147	CcSEcCtD
Methotrexate—Thrombocytopenia—Capecitabine—prostate cancer	1.16e-05	0.000147	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—prostate cancer	1.16e-05	0.000146	CcSEcCtD
Methotrexate—Skin disorder—Capecitabine—prostate cancer	1.15e-05	0.000146	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—prostate cancer	1.15e-05	0.000145	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—prostate cancer	1.15e-05	0.000145	CcSEcCtD
Methotrexate—Hyperhidrosis—Capecitabine—prostate cancer	1.15e-05	0.000145	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—prostate cancer	1.15e-05	0.000145	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—prostate cancer	1.15e-05	0.000144	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—prostate cancer	1.14e-05	0.000144	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—prostate cancer	1.14e-05	0.000143	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—prostate cancer	1.13e-05	0.000143	CcSEcCtD
Methotrexate—Anorexia—Capecitabine—prostate cancer	1.13e-05	0.000143	CcSEcCtD
Methotrexate—Nausea—Estradiol—prostate cancer	1.13e-05	0.000143	CcSEcCtD
Methotrexate—Vomiting—Mitoxantrone—prostate cancer	1.13e-05	0.000142	CcSEcCtD
Methotrexate—Convulsion—Prednisone—prostate cancer	1.12e-05	0.000142	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—prostate cancer	1.12e-05	0.000142	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—prostate cancer	1.12e-05	0.000141	CcSEcCtD
Methotrexate—Rash—Mitoxantrone—prostate cancer	1.12e-05	0.000141	CcSEcCtD
Methotrexate—Dermatitis—Mitoxantrone—prostate cancer	1.12e-05	0.000141	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—prostate cancer	1.12e-05	0.000141	CcSEcCtD
Methotrexate—Headache—Mitoxantrone—prostate cancer	1.11e-05	0.00014	CcSEcCtD
Methotrexate—Hypotension—Capecitabine—prostate cancer	1.11e-05	0.00014	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—prostate cancer	1.11e-05	0.00014	CcSEcCtD
Methotrexate—Arthralgia—Prednisone—prostate cancer	1.1e-05	0.000139	CcSEcCtD
Methotrexate—Myalgia—Prednisone—prostate cancer	1.1e-05	0.000139	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—prostate cancer	1.1e-05	0.000139	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—prostate cancer	1.1e-05	0.000139	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	1.1e-05	0.000138	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—prostate cancer	1.09e-05	0.000138	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—prostate cancer	1.09e-05	0.000138	CcSEcCtD
Methotrexate—Discomfort—Prednisone—prostate cancer	1.09e-05	0.000138	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—prostate cancer	1.09e-05	0.000137	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—prostate cancer	1.09e-05	0.000137	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—prostate cancer	1.09e-05	0.000137	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—prostate cancer	1.08e-05	0.000137	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.08e-05	0.000137	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—prostate cancer	1.08e-05	0.000136	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—prostate cancer	1.08e-05	0.000136	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—prostate cancer	1.08e-05	0.000136	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—prostate cancer	1.08e-05	0.000136	CcSEcCtD
Methotrexate—Insomnia—Capecitabine—prostate cancer	1.07e-05	0.000136	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—prostate cancer	1.07e-05	0.000135	CcSEcCtD
Methotrexate—Paraesthesia—Capecitabine—prostate cancer	1.07e-05	0.000135	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—prostate cancer	1.07e-05	0.000135	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Asthenia—Etoposide—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Dyspnoea—Capecitabine—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisone—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—prostate cancer	1.06e-05	0.000134	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—prostate cancer	1.06e-05	0.000133	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—prostate cancer	1.06e-05	0.000133	CcSEcCtD
Methotrexate—Nausea—Mitoxantrone—prostate cancer	1.05e-05	0.000133	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—prostate cancer	1.05e-05	0.000133	CcSEcCtD
Methotrexate—Infection—Prednisone—prostate cancer	1.05e-05	0.000133	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—prostate cancer	1.05e-05	0.000133	CcSEcCtD
Methotrexate—Pain—Docetaxel—prostate cancer	1.05e-05	0.000132	CcSEcCtD
Methotrexate—Dyspepsia—Capecitabine—prostate cancer	1.05e-05	0.000132	CcSEcCtD
Methotrexate—Chills—Epirubicin—prostate cancer	1.05e-05	0.000132	CcSEcCtD
Methotrexate—Pruritus—Etoposide—prostate cancer	1.04e-05	0.000132	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—prostate cancer	1.04e-05	0.000131	CcSEcCtD
Methotrexate—Nervous system disorder—Prednisone—prostate cancer	1.04e-05	0.000131	CcSEcCtD
Methotrexate—Decreased appetite—Capecitabine—prostate cancer	1.03e-05	0.00013	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—prostate cancer	1.03e-05	0.00013	CcSEcCtD
Methotrexate—Skin disorder—Prednisone—prostate cancer	1.03e-05	0.00013	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Capecitabine—prostate cancer	1.03e-05	0.000129	CcSEcCtD
Methotrexate—Fatigue—Capecitabine—prostate cancer	1.02e-05	0.000129	CcSEcCtD
Methotrexate—Hyperhidrosis—Prednisone—prostate cancer	1.02e-05	0.000129	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—prostate cancer	1.02e-05	0.000129	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—prostate cancer	1.02e-05	0.000129	CcSEcCtD
Methotrexate—Pain—Capecitabine—prostate cancer	1.02e-05	0.000128	CcSEcCtD
Methotrexate—Erythema—Epirubicin—prostate cancer	1.01e-05	0.000128	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—prostate cancer	1.01e-05	0.000128	CcSEcCtD
Methotrexate—Feeling abnormal—Docetaxel—prostate cancer	1.01e-05	0.000128	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—prostate cancer	1.01e-05	0.000128	CcSEcCtD
Methotrexate—Anorexia—Prednisone—prostate cancer	1.01e-05	0.000127	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—prostate cancer	1.01e-05	0.000127	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—prostate cancer	1.01e-05	0.000127	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—prostate cancer	1e-05	0.000127	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—prostate cancer	1e-05	0.000126	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—prostate cancer	9.93e-06	0.000125	CcSEcCtD
Methotrexate—Back pain—Epirubicin—prostate cancer	9.81e-06	0.000124	CcSEcCtD
Methotrexate—Feeling abnormal—Capecitabine—prostate cancer	9.79e-06	0.000124	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—prostate cancer	9.78e-06	0.000123	CcSEcCtD
Methotrexate—Dizziness—Etoposide—prostate cancer	9.77e-06	0.000123	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—prostate cancer	9.74e-06	0.000123	CcSEcCtD
Methotrexate—Gastrointestinal pain—Capecitabine—prostate cancer	9.72e-06	0.000123	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—prostate cancer	9.72e-06	0.000123	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—prostate cancer	9.7e-06	0.000122	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—prostate cancer	9.7e-06	0.000122	CcSEcCtD
Methotrexate—Chills—Doxorubicin—prostate cancer	9.67e-06	0.000122	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Prednisone—prostate cancer	9.64e-06	0.000122	CcSEcCtD
Methotrexate—Insomnia—Prednisone—prostate cancer	9.57e-06	0.000121	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—prostate cancer	9.56e-06	0.000121	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—prostate cancer	9.53e-06	0.00012	CcSEcCtD
Methotrexate—Paraesthesia—Prednisone—prostate cancer	9.5e-06	0.00012	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—prostate cancer	9.44e-06	0.000119	CcSEcCtD
Methotrexate—Urticaria—Capecitabine—prostate cancer	9.44e-06	0.000119	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—prostate cancer	9.41e-06	0.000119	CcSEcCtD
Methotrexate—Abdominal pain—Capecitabine—prostate cancer	9.39e-06	0.000119	CcSEcCtD
Methotrexate—Body temperature increased—Capecitabine—prostate cancer	9.39e-06	0.000119	CcSEcCtD
Methotrexate—Vomiting—Etoposide—prostate cancer	9.39e-06	0.000118	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—prostate cancer	9.38e-06	0.000118	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—prostate cancer	9.38e-06	0.000118	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—prostate cancer	9.37e-06	0.000118	CcSEcCtD
Methotrexate—Dyspepsia—Prednisone—prostate cancer	9.32e-06	0.000118	CcSEcCtD
Methotrexate—Rash—Etoposide—prostate cancer	9.31e-06	0.000117	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—prostate cancer	9.3e-06	0.000117	CcSEcCtD
Methotrexate—Headache—Etoposide—prostate cancer	9.25e-06	0.000117	CcSEcCtD
Methotrexate—Decreased appetite—Prednisone—prostate cancer	9.2e-06	0.000116	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—prostate cancer	9.19e-06	0.000116	CcSEcCtD
Methotrexate—Malaise—Epirubicin—prostate cancer	9.15e-06	0.000115	CcSEcCtD
Methotrexate—Fatigue—Prednisone—prostate cancer	9.12e-06	0.000115	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—prostate cancer	9.11e-06	0.000115	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—prostate cancer	9.08e-06	0.000115	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—prostate cancer	9.08e-06	0.000115	CcSEcCtD
Methotrexate—Hypersensitivity—Docetaxel—prostate cancer	9.04e-06	0.000114	CcSEcCtD
Methotrexate—Cough—Epirubicin—prostate cancer	8.85e-06	0.000112	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—prostate cancer	8.84e-06	0.000112	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—prostate cancer	8.81e-06	0.000111	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—prostate cancer	8.79e-06	0.000111	CcSEcCtD
Methotrexate—Nausea—Etoposide—prostate cancer	8.77e-06	0.000111	CcSEcCtD
Methotrexate—Hypersensitivity—Capecitabine—prostate cancer	8.75e-06	0.00011	CcSEcCtD
Methotrexate—Feeling abnormal—Prednisone—prostate cancer	8.72e-06	0.00011	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—prostate cancer	8.71e-06	0.00011	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—prostate cancer	8.68e-06	0.00011	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—prostate cancer	8.67e-06	0.000109	CcSEcCtD
Methotrexate—Gastrointestinal pain—Prednisone—prostate cancer	8.65e-06	0.000109	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—prostate cancer	8.63e-06	0.000109	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—prostate cancer	8.63e-06	0.000109	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—prostate cancer	8.63e-06	0.000109	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.58e-06	0.000108	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—prostate cancer	8.53e-06	0.000108	CcSEcCtD
Methotrexate—Asthenia—Capecitabine—prostate cancer	8.52e-06	0.000108	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—prostate cancer	8.46e-06	0.000107	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—prostate cancer	8.43e-06	0.000106	CcSEcCtD
Methotrexate—Urticaria—Prednisone—prostate cancer	8.41e-06	0.000106	CcSEcCtD
Methotrexate—Pruritus—Capecitabine—prostate cancer	8.41e-06	0.000106	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—prostate cancer	8.4e-06	0.000106	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—prostate cancer	8.4e-06	0.000106	CcSEcCtD
Methotrexate—Abdominal pain—Prednisone—prostate cancer	8.37e-06	0.000106	CcSEcCtD
Methotrexate—Body temperature increased—Prednisone—prostate cancer	8.37e-06	0.000106	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—prostate cancer	8.35e-06	0.000105	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—prostate cancer	8.28e-06	0.000104	CcSEcCtD
Methotrexate—Infection—Epirubicin—prostate cancer	8.22e-06	0.000104	CcSEcCtD
Methotrexate—Cough—Doxorubicin—prostate cancer	8.19e-06	0.000103	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—prostate cancer	8.13e-06	0.000103	CcSEcCtD
Methotrexate—Diarrhoea—Capecitabine—prostate cancer	8.13e-06	0.000103	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—prostate cancer	8.12e-06	0.000102	CcSEcCtD
Methotrexate—Dizziness—Docetaxel—prostate cancer	8.12e-06	0.000102	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—prostate cancer	8.1e-06	0.000102	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—prostate cancer	8.04e-06	0.000101	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—prostate cancer	8e-06	0.000101	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—prostate cancer	7.99e-06	0.000101	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—prostate cancer	7.99e-06	0.000101	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—prostate cancer	7.99e-06	0.000101	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	7.93e-06	0.0001	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—prostate cancer	7.89e-06	9.96e-05	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—prostate cancer	7.89e-06	9.96e-05	CcSEcCtD
Methotrexate—Dizziness—Capecitabine—prostate cancer	7.86e-06	9.92e-05	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—prostate cancer	7.8e-06	9.85e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Prednisone—prostate cancer	7.8e-06	9.84e-05	CcSEcCtD
Methotrexate—Rash—Docetaxel—prostate cancer	7.74e-06	9.76e-05	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—prostate cancer	7.73e-06	9.76e-05	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—prostate cancer	7.73e-06	9.76e-05	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—prostate cancer	7.72e-06	9.75e-05	CcSEcCtD
Methotrexate—Headache—Docetaxel—prostate cancer	7.69e-06	9.7e-05	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—prostate cancer	7.66e-06	9.67e-05	CcSEcCtD
Methotrexate—Infection—Doxorubicin—prostate cancer	7.61e-06	9.6e-05	CcSEcCtD
Methotrexate—Asthenia—Prednisone—prostate cancer	7.59e-06	9.58e-05	CcSEcCtD
Methotrexate—Vomiting—Capecitabine—prostate cancer	7.55e-06	9.53e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—prostate cancer	7.54e-06	9.52e-05	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—prostate cancer	7.51e-06	9.48e-05	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—prostate cancer	7.5e-06	9.46e-05	CcSEcCtD
Methotrexate—Rash—Capecitabine—prostate cancer	7.49e-06	9.45e-05	CcSEcCtD
Methotrexate—Pruritus—Prednisone—prostate cancer	7.49e-06	9.45e-05	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—prostate cancer	7.49e-06	9.45e-05	CcSEcCtD
Methotrexate—Dermatitis—Capecitabine—prostate cancer	7.48e-06	9.45e-05	CcSEcCtD
Methotrexate—Headache—Capecitabine—prostate cancer	7.44e-06	9.39e-05	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—prostate cancer	7.44e-06	9.39e-05	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—prostate cancer	7.43e-06	9.38e-05	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—prostate cancer	7.4e-06	9.34e-05	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—prostate cancer	7.38e-06	9.31e-05	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—prostate cancer	7.36e-06	9.29e-05	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—prostate cancer	7.3e-06	9.21e-05	CcSEcCtD
Methotrexate—Nausea—Docetaxel—prostate cancer	7.29e-06	9.2e-05	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—prostate cancer	7.29e-06	9.2e-05	CcSEcCtD
Methotrexate—Diarrhoea—Prednisone—prostate cancer	7.24e-06	9.14e-05	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—prostate cancer	7.2e-06	9.08e-05	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—prostate cancer	7.16e-06	9.03e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—prostate cancer	7.15e-06	9.02e-05	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—prostate cancer	7.14e-06	9.01e-05	CcSEcCtD
Methotrexate—Pain—Epirubicin—prostate cancer	7.08e-06	8.93e-05	CcSEcCtD
Methotrexate—Nausea—Capecitabine—prostate cancer	7.06e-06	8.91e-05	CcSEcCtD
Methotrexate—Dizziness—Prednisone—prostate cancer	7e-06	8.83e-05	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.98e-06	8.81e-05	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—prostate cancer	6.93e-06	8.74e-05	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—prostate cancer	6.88e-06	8.68e-05	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—prostate cancer	6.83e-06	8.62e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—prostate cancer	6.82e-06	8.61e-05	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—prostate cancer	6.81e-06	8.59e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—prostate cancer	6.77e-06	8.54e-05	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—prostate cancer	6.74e-06	8.51e-05	CcSEcCtD
Methotrexate—Vomiting—Prednisone—prostate cancer	6.73e-06	8.49e-05	CcSEcCtD
Methotrexate—Rash—Prednisone—prostate cancer	6.67e-06	8.42e-05	CcSEcCtD
Methotrexate—Dermatitis—Prednisone—prostate cancer	6.67e-06	8.41e-05	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—prostate cancer	6.66e-06	8.4e-05	CcSEcCtD
Methotrexate—Headache—Prednisone—prostate cancer	6.63e-06	8.37e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.61e-06	8.34e-05	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—prostate cancer	6.6e-06	8.33e-05	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—prostate cancer	6.58e-06	8.3e-05	CcSEcCtD
Methotrexate—Pain—Doxorubicin—prostate cancer	6.55e-06	8.27e-05	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—prostate cancer	6.54e-06	8.26e-05	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—prostate cancer	6.54e-06	8.26e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—prostate cancer	6.31e-06	7.96e-05	CcSEcCtD
Methotrexate—Nausea—Prednisone—prostate cancer	6.29e-06	7.93e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—prostate cancer	6.26e-06	7.9e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—prostate cancer	6.1e-06	7.7e-05	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—prostate cancer	6.08e-06	7.68e-05	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—prostate cancer	6.05e-06	7.64e-05	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—prostate cancer	6.05e-06	7.64e-05	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—prostate cancer	5.94e-06	7.49e-05	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—prostate cancer	5.86e-06	7.39e-05	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—prostate cancer	5.66e-06	7.15e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—prostate cancer	5.64e-06	7.12e-05	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—prostate cancer	5.5e-06	6.93e-05	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—prostate cancer	5.47e-06	6.91e-05	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—prostate cancer	5.42e-06	6.84e-05	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—prostate cancer	5.26e-06	6.64e-05	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—prostate cancer	5.24e-06	6.61e-05	CcSEcCtD
Methotrexate—Rash—Epirubicin—prostate cancer	5.22e-06	6.59e-05	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—prostate cancer	5.21e-06	6.58e-05	CcSEcCtD
Methotrexate—Headache—Epirubicin—prostate cancer	5.19e-06	6.54e-05	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—prostate cancer	5.06e-06	6.39e-05	CcSEcCtD
Methotrexate—Nausea—Epirubicin—prostate cancer	4.92e-06	6.2e-05	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—prostate cancer	4.87e-06	6.15e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—prostate cancer	4.83e-06	6.09e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—prostate cancer	4.82e-06	6.09e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—prostate cancer	4.8e-06	6.06e-05	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—prostate cancer	4.55e-06	5.74e-05	CcSEcCtD
Methotrexate—ABCG2—Metabolism—GSTM1—prostate cancer	9.15e-07	1.64e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGDS—prostate cancer	9.14e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CREBBP—prostate cancer	9.14e-07	1.63e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—prostate cancer	9.12e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGF—prostate cancer	9.11e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS1—prostate cancer	9.11e-07	1.63e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—prostate cancer	9.1e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—prostate cancer	9.09e-07	1.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2C19—prostate cancer	9.08e-07	1.62e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NOS3—prostate cancer	9.07e-07	1.62e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—prostate cancer	9.04e-07	1.62e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—prostate cancer	9.03e-07	1.62e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARA—prostate cancer	9.02e-07	1.61e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9e-07	1.61e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SERPINE1—prostate cancer	8.99e-07	1.61e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—LPL—prostate cancer	8.98e-07	1.61e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—prostate cancer	8.96e-07	1.6e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—prostate cancer	8.94e-07	1.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SULT2A1—prostate cancer	8.93e-07	1.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	8.93e-07	1.6e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—prostate cancer	8.88e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—prostate cancer	8.86e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ACHE—prostate cancer	8.86e-07	1.59e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—GSK3B—prostate cancer	8.85e-07	1.58e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MED12—prostate cancer	8.78e-07	1.57e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—prostate cancer	8.77e-07	1.57e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2A6—prostate cancer	8.76e-07	1.57e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—prostate cancer	8.73e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.73e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—INS—prostate cancer	8.73e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—prostate cancer	8.72e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNG5—prostate cancer	8.71e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—prostate cancer	8.67e-07	1.55e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—prostate cancer	8.66e-07	1.55e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—prostate cancer	8.61e-07	1.54e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ERCC2—prostate cancer	8.6e-07	1.54e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS3—prostate cancer	8.58e-07	1.54e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—prostate cancer	8.58e-07	1.53e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARA—prostate cancer	8.57e-07	1.53e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—prostate cancer	8.56e-07	1.53e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREBBP—prostate cancer	8.55e-07	1.53e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKR1C3—prostate cancer	8.52e-07	1.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PRKACB—prostate cancer	8.48e-07	1.52e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAV1—prostate cancer	8.48e-07	1.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA3—prostate cancer	8.39e-07	1.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP17A1—prostate cancer	8.39e-07	1.5e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—prostate cancer	8.37e-07	1.5e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—prostate cancer	8.36e-07	1.5e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—JAK2—prostate cancer	8.34e-07	1.49e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	8.3e-07	1.48e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—prostate cancer	8.29e-07	1.48e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—prostate cancer	8.28e-07	1.48e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.28e-07	1.48e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—prostate cancer	8.23e-07	1.47e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NOS3—prostate cancer	8.18e-07	1.46e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAP2K1—prostate cancer	8.16e-07	1.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—INS—prostate cancer	8.12e-07	1.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—prostate cancer	8.1e-07	1.45e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.1e-07	1.45e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—prostate cancer	8.09e-07	1.45e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAV1—prostate cancer	8.06e-07	1.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SERPINE1—prostate cancer	8.02e-07	1.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGDS—prostate cancer	8.01e-07	1.43e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA2—prostate cancer	7.99e-07	1.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2C19—prostate cancer	7.96e-07	1.42e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CREBBP—prostate cancer	7.96e-07	1.42e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARA—prostate cancer	7.93e-07	1.42e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—prostate cancer	7.92e-07	1.42e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—prostate cancer	7.88e-07	1.41e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—prostate cancer	7.85e-07	1.4e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—prostate cancer	7.77e-07	1.39e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ACHE—prostate cancer	7.77e-07	1.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGF2—prostate cancer	7.76e-07	1.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—prostate cancer	7.72e-07	1.38e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.7e-07	1.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2A6—prostate cancer	7.68e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	7.65e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS3—prostate cancer	7.65e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—prostate cancer	7.63e-07	1.36e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—prostate cancer	7.61e-07	1.36e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—prostate cancer	7.58e-07	1.36e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—prostate cancer	7.55e-07	1.35e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—prostate cancer	7.54e-07	1.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	7.54e-07	1.35e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—prostate cancer	7.52e-07	1.34e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—prostate cancer	7.48e-07	1.34e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKR1C3—prostate cancer	7.47e-07	1.34e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAV1—prostate cancer	7.46e-07	1.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2E1—prostate cancer	7.45e-07	1.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—JAK2—prostate cancer	7.44e-07	1.33e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PRKACB—prostate cancer	7.43e-07	1.33e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—prostate cancer	7.41e-07	1.32e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NQO1—prostate cancer	7.37e-07	1.32e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP17A1—prostate cancer	7.35e-07	1.31e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—prostate cancer	7.34e-07	1.31e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—INS—prostate cancer	7.31e-07	1.31e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—prostate cancer	7.28e-07	1.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	7.27e-07	1.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—prostate cancer	7.26e-07	1.3e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TH—prostate cancer	7.26e-07	1.3e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—prostate cancer	7.23e-07	1.29e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.21e-07	1.29e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP3A4—prostate cancer	7.18e-07	1.28e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—prostate cancer	7.17e-07	1.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CREBBP—prostate cancer	7.16e-07	1.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—prostate cancer	7.16e-07	1.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.15e-07	1.28e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NOS3—prostate cancer	7.12e-07	1.27e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—prostate cancer	7.06e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1B1—prostate cancer	7.06e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA2—prostate cancer	7.01e-07	1.25e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—prostate cancer	7e-07	1.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—prostate cancer	7e-07	1.25e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—prostate cancer	7e-07	1.25e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—INS—prostate cancer	6.95e-07	1.24e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—prostate cancer	6.9e-07	1.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GGT1—prostate cancer	6.84e-07	1.22e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—prostate cancer	6.83e-07	1.22e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CREBBP—prostate cancer	6.8e-07	1.22e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—prostate cancer	6.79e-07	1.22e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—prostate cancer	6.79e-07	1.21e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—prostate cancer	6.74e-07	1.21e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA1—prostate cancer	6.74e-07	1.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—prostate cancer	6.68e-07	1.2e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—prostate cancer	6.64e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—prostate cancer	6.63e-07	1.19e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—prostate cancer	6.57e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—prostate cancer	6.53e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2E1—prostate cancer	6.53e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—prostate cancer	6.52e-07	1.17e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—prostate cancer	6.51e-07	1.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NQO1—prostate cancer	6.45e-07	1.15e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—prostate cancer	6.45e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—INS—prostate cancer	6.43e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NOS3—prostate cancer	6.41e-07	1.15e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—RXRA—prostate cancer	6.41e-07	1.15e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—prostate cancer	6.37e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TH—prostate cancer	6.36e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—prostate cancer	6.35e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CREBBP—prostate cancer	6.3e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP3A4—prostate cancer	6.29e-07	1.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—prostate cancer	6.26e-07	1.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.23e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—prostate cancer	6.22e-07	1.11e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—prostate cancer	6.22e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1B1—prostate cancer	6.19e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—prostate cancer	6.18e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—COMT—prostate cancer	6.17e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—prostate cancer	6.14e-07	1.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—prostate cancer	6.12e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—prostate cancer	6.1e-07	1.09e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NOS3—prostate cancer	6.09e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ITPR1—prostate cancer	6.05e-07	1.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GGT1—prostate cancer	5.99e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—prostate cancer	5.97e-07	1.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.94e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—prostate cancer	5.92e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA1—prostate cancer	5.9e-07	1.06e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—prostate cancer	5.86e-07	1.05e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—prostate cancer	5.86e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—prostate cancer	5.82e-07	1.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—prostate cancer	5.82e-07	1.04e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—prostate cancer	5.8e-07	1.04e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—prostate cancer	5.72e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—prostate cancer	5.71e-07	1.02e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—prostate cancer	5.68e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—prostate cancer	5.68e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—prostate cancer	5.66e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—prostate cancer	5.65e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NOS3—prostate cancer	5.64e-07	1.01e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—prostate cancer	5.62e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—RXRA—prostate cancer	5.61e-07	1e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—prostate cancer	5.57e-07	9.96e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—prostate cancer	5.56e-07	9.94e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LPL—prostate cancer	5.54e-07	9.91e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—prostate cancer	5.46e-07	9.76e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—prostate cancer	5.42e-07	9.69e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—COMT—prostate cancer	5.41e-07	9.67e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—prostate cancer	5.38e-07	9.63e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—prostate cancer	5.35e-07	9.57e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ERCC2—prostate cancer	5.31e-07	9.49e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ITPR1—prostate cancer	5.3e-07	9.47e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—prostate cancer	5.26e-07	9.4e-06	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—prostate cancer	5.21e-07	9.31e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—prostate cancer	5.21e-07	9.31e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—prostate cancer	5.16e-07	9.22e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—prostate cancer	5.11e-07	9.14e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—prostate cancer	5.1e-07	9.12e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—prostate cancer	5.07e-07	9.07e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—prostate cancer	5.06e-07	9.05e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—prostate cancer	5e-07	8.95e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—prostate cancer	4.99e-07	8.92e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—prostate cancer	4.96e-07	8.87e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—prostate cancer	4.95e-07	8.85e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARA—prostate cancer	4.9e-07	8.75e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—prostate cancer	4.88e-07	8.72e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—prostate cancer	4.86e-07	8.69e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LPL—prostate cancer	4.86e-07	8.68e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—prostate cancer	4.83e-07	8.64e-06	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—prostate cancer	4.74e-07	8.48e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—prostate cancer	4.69e-07	8.39e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—prostate cancer	4.69e-07	8.38e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—prostate cancer	4.67e-07	8.36e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ERCC2—prostate cancer	4.65e-07	8.32e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—prostate cancer	4.63e-07	8.29e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—prostate cancer	4.6e-07	8.23e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAV1—prostate cancer	4.6e-07	8.23e-06	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—prostate cancer	4.54e-07	8.12e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—prostate cancer	4.5e-07	8.04e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.4e-07	7.86e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—prostate cancer	4.37e-07	7.82e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—prostate cancer	4.31e-07	7.7e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—prostate cancer	4.29e-07	7.67e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARA—prostate cancer	4.29e-07	7.67e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—prostate cancer	4.19e-07	7.5e-06	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—prostate cancer	4.17e-07	7.45e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAV1—prostate cancer	4.03e-07	7.21e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—prostate cancer	4.01e-07	7.17e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—INS—prostate cancer	3.97e-07	7.1e-06	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—prostate cancer	3.95e-07	7.06e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CREBBP—prostate cancer	3.89e-07	6.95e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—prostate cancer	3.81e-07	6.82e-06	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—prostate cancer	3.76e-07	6.72e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—prostate cancer	3.69e-07	6.59e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—prostate cancer	3.67e-07	6.57e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—prostate cancer	3.61e-07	6.45e-06	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—prostate cancer	3.52e-07	6.29e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NOS3—prostate cancer	3.48e-07	6.22e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—INS—prostate cancer	3.48e-07	6.22e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—prostate cancer	3.43e-07	6.13e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CREBBP—prostate cancer	3.41e-07	6.09e-06	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—prostate cancer	3.27e-07	5.86e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—prostate cancer	3.23e-07	5.77e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—prostate cancer	3.21e-07	5.74e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—prostate cancer	3.18e-07	5.69e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—prostate cancer	3.17e-07	5.68e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NOS3—prostate cancer	3.05e-07	5.45e-06	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—prostate cancer	2.95e-07	5.27e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—prostate cancer	2.81e-07	5.03e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—prostate cancer	2.8e-07	5.01e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—prostate cancer	2.79e-07	4.99e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—prostate cancer	2.78e-07	4.96e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—prostate cancer	2.65e-07	4.73e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—prostate cancer	2.59e-07	4.64e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—prostate cancer	2.43e-07	4.35e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—prostate cancer	2.32e-07	4.15e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—prostate cancer	1.96e-07	3.5e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—prostate cancer	1.72e-07	3.07e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—prostate cancer	1.6e-07	2.86e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—prostate cancer	1.4e-07	2.51e-06	CbGpPWpGaD
